Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Eli Lilly & Co. will pay Germany’s BioNTech $30 million to develop cancer immunotherapies. The partners will identify tumor targets and their related functional T-cell receptors, which together can be engineered into therapies. Lilly will also take a stake worth $30 million in the biotech firm’s subsidiary Cell & Gene Therapies. In a separate cancer immunotherapy deal, Juno Therapeutics paid about $59 million in cash and $21 million in stock to acquire Stage Cell Therapeutics, a German biotech with expertise in cellular therapy manufacturing. Juno already owned a 5% stake in the firm.
This article has been sent to the following recipient: